NCT01486888View on ClinicalTrials.gov

Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

DiabetesHealthy

Interventions

DRUG

biphasic human insulin 30

Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY